Cargando…

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist

Introduction: The development of Glucagon like peptide-1 (GLP-1) receptors agonists represents an important advancement in the management of type 2 diabetes. The long-acting GLP-1 receptor agonists improve glycemic control, promote weight loss. Anaphylaxis to GLP-1 receptor agonists and mainly Dulag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quadri, Hamza, Ataallah, Basma, Haggerty, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090007/ http://dx.doi.org/10.1210/jendso/bvab048.748

Ejemplares similares

A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes
por: Sato, Tetsuhiko, et al.
Publicado: (2021)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus
por: Fazeli, Sasan, et al.
Publicado: (2019)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

MON-LB032 Real World Evidence Data on the Role of Sodium/Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist in Chronic Kidney Disease Stage 3 Patients beyond Glycemic Control, at Glycemia Clinic- Kuwait
por: Shaghouli, Amna, et al.
Publicado: (2019)

SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY
por: Tyler Broome, David
Publicado: (2023)

MON-681 Dulaglutide Commonly Known as Trulicity; An Anti-Diabetic Medication Causing Small Bowel Obstruction
por: Gandhi, Ankita, et al.
Publicado: (2020)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

FRI646 Dulaglutide-induced Acute Liver Injury - A Case Report
por: Shahid, Maham, et al.
Publicado: (2023)

Scientific and Regulatory Considerations for the Approval of the First Generic Glucagon
por: Pang, Eric, et al.
Publicado: (2021)

OR28-5 Bile Acid Sequestration Accelerates Glucagon Receptor-Mediated Body Weight Loss in Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2019)

SAT-655 Bile Acid Sequestration Synergistically Accelerates Glucagon Receptor-Stimulated Body Weight Loss in Diet-Induced Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2020)

OR22-3 Closed-Loop Glucagon Pump: A Novel and Effective Strategy for Post-Bariatric Hypoglycemia
por: Mulla, Christopher, et al.
Publicado: (2019)

OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)
por: Frias, Juan Pablo, et al.
Publicado: (2020)

MON-LB115 Ready-To-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia in a Clinical Research Setting
por: Aronson, Ronnie, et al.
Publicado: (2020)

THU275 Tacrolimus Levels And Kidney Function In Kidney Transplanted (KT) Patients With Diabetes On Glucagon Like-1 Receptor Agonists (GLP1-RA)
por: Campana, Mario S, et al.
Publicado: (2023)

Characterization of Viral Insulin-Like Peptides Reveals Unique White Adipose Tissue Specific Characteristics
por: Chrudinova, Martina, et al.
Publicado: (2021)

THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes
por: Reddy Ankireddypalli, Anvitha, et al.
Publicado: (2023)

Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis
por: Piccoli, Giovana Fagundes, et al.
Publicado: (2021)

THU338 Risks Of Stroke, Its Subtypes And Atrial Fibrillation Associated With Glucagon-like Peptide 1 Receptor Agonists Versus Sodium-glucose Cotransporter 2 Inhibitors: A Real-world Population-based Study In Hong Kong
por: Lui, David, et al.
Publicado: (2023)

MON-646 Novel Use of GLP-1 Receptor Agonist Therapy in MODY-1 (HNF4A Mutation)
por: Broome, David Tyler, et al.
Publicado: (2020)

OR26-07 Mild Physiologic Hyperglycemia Does Not Affect Glucose Mediated but Impairs Insulin-Mediated Suppression of Plasma Glucagon in Healthy Normal Glucose Tolerant Subjects
por: Tripathy, Devjit, et al.
Publicado: (2020)

Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist
por: Shaghouli, Amna Ali, et al.
Publicado: (2021)

MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure
por: Pettus, Jeremy H, et al.
Publicado: (2020)

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion
por: Douglas Galsgaard, Katrine, et al.
Publicado: (2023)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

SUN-165 The Largest Single-Center Experience of GLP-1 Receptor Agonists as a Safe and Effective Agent for the Management of Diabetes in Solid Organ Transplant (SOT) Recipients
por: Singh, Priyamvada, et al.
Publicado: (2019)

Glycogenic Hepatopathy in a Patient with Pancreatogenic Diabetes
por: Baggett, A Brooke, et al.
Publicado: (2021)

SAT-169 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-Induced Insulin Secretion in Rats
por: Sturchler, Emmanuel, et al.
Publicado: (2019)

OR05-5 AZP-3404, a 9-Amino Acid Peptide Analog of Insulin-Like Growth Factor-Binding Protein 2, Reverses Insulin Resistance in Leptin-Deficient ob/ob Mice
por: Milano, Stephane, et al.
Publicado: (2019)

PSUN241 A Case of Dulaglutide-Induced Acute Pancreatitis in a Diabetic Patient – A Case Report
por: Abdelmasih, Randa, et al.
Publicado: (2022)

SUN-660 Appetite Suppressing Effects of Glucoregulatory Chimeric Peptides Devoid of Nausea
por: Roth, Christian Ludwig, et al.
Publicado: (2020)

Selective Somatostatin 5 (SST5) and Somatostatin 2 (SST2) Nonpeptide Agonists Potently Suppress Glucose- and Tolbutamide-Stimulated Dynamic Insulin Secretion From Isolated Human Islets
por: Rico, Elizabeth, et al.
Publicado: (2021)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides
por: Yau, Alice, et al.
Publicado: (2022)

MON-623 Pattern of C-Peptide Response to Oral Glucose Tolerance Test: Interest and Cut-Off Values
por: Bonnet-Serrano, Fidéline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gk47tipt8ta8d5p3puparodmij